Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Guardant Health Inc (GH)

Guardant Health Inc (GH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,006,791
  • Shares Outstanding, K 101,299
  • Annual Sales, $ 286,730 K
  • Annual Income, $ -253,780 K
  • 60-Month Beta 0.51
  • Price/Sales 45.69
  • Price/Cash Flow N/A
  • Price/Book 16.93
Trade GH with:

Options Overview Details

View History
  • Implied Volatility 46.29%
  • Historical Volatility 29.33%
  • IV Percentile 18%
  • IV Rank 19.55%
  • IV High 70.08% on 10/30/20
  • IV Low 40.51% on 09/08/21
  • Put/Call Vol Ratio 2.03
  • Today's Volume 837
  • Volume Avg (30-Day) 520
  • Put/Call OI Ratio 0.41
  • Today's Open Interest 4,725
  • Open Int (30-Day) 5,402

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.94
  • Number of Estimates 6
  • High Estimate -0.33
  • Low Estimate -1.15
  • Prior Year -0.78
  • Growth Rate Est. (year over year) -20.51%

Price Performance

See More
Period Period Low Period High Performance
1-Month
112.55 +14.08%
on 08/25/21
133.82 -4.05%
on 09/02/21
+14.73 (+12.96%)
since 08/24/21
3-Month
96.66 +32.84%
on 08/17/21
133.82 -4.05%
on 09/02/21
+2.59 (+2.06%)
since 06/24/21
52-Week
96.66 +32.84%
on 08/17/21
181.07 -29.09%
on 02/12/21
+22.00 (+20.68%)
since 09/24/20

Most Recent Stories

More News
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360(R) Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers

Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages...

GH : 128.40 (-0.71%)
New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Advantages of Using the Guardant360(R) Liquid Biopsy Blood Test for Comprehensive Genomic Profiling in Advanced Lung Cancer

Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360liquid biopsy test for clinical...

GH : 128.40 (-0.71%)
uLab Announces Appointment of Three New Board Members

/PRNewswire/ -- uLab Systems, creator of uSmile™ clear aligners and uDesign™ treatment planning software, announced today the appointment of three new members to its Board of Directors: , AmirAli Talasaz,...

GH : 128.40 (-0.71%)
Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -10.34% and 8.82%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

GH : 128.40 (-0.71%)
Guardant Health: Q2 Earnings Snapshot

REDWOOD CITY, Calif. (AP) _ Guardant Health Inc. (GH) on Thursday reported a loss of $97.6 million in its second quarter.

GH : 128.40 (-0.71%)
Bear of the Day: NeoGenomics (NEO)

Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff

NEO : 46.86 (-6.17%)
EXAS : 96.02 (-2.24%)
NVTA : 30.06 (-6.62%)
NTRA : 118.12 (-4.39%)
GH : 128.40 (-0.71%)
Mixed Session as Fed, Earnings Compete For Market’s Attention

Mixed Session as Fed, Earnings Compete For Market’s Attention

LPRO : 38.43 (-0.80%)
FND : 130.77 (+0.28%)
AKAM : 110.13 (+1.25%)
GH : 128.40 (-0.71%)
NTRA : 118.12 (-4.39%)
ALNY : 187.40 (+0.24%)
LAZR : 16.83 (-2.83%)
VECO : 22.38 (-1.50%)
NEP : 78.30 (-0.27%)
TLRY : 11.67 (-2.91%)
OGI : 2.42 (-3.20%)
GOOGL : 2,844.30 (+0.71%)
MSFT : 299.35 (-0.07%)
AAPL : 146.92 (+0.06%)
FB : 352.96 (+2.02%)
AMZN : 3,425.52 (+0.28%)
MA : 358.16 (+1.16%)
CMCSA : 56.24 (+0.12%)
MRK : 73.61 (+0.77%)
TMUS : 129.43 (-1.15%)
AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding Round

Souh Korea, July 19, 2021 /PRNewswire/ -- Lunit, a leading AI startup in AI-powered cancer solutions, today announced a strategic investment of from Guardant Health, Inc. (Nasdaq: GH), a leading precision...

GH : 128.40 (-0.71%)
Bull of the Day: Exact Sciences (EXAS)

EPS surprises abound as Cologuard and Precision Oncology grow sales 20% into next year

EXAS : 96.02 (-2.24%)
ADPT : 36.49 (-6.96%)
NVTA : 30.06 (-6.62%)
NTRA : 118.12 (-4.39%)
GH : 128.40 (-0.71%)
New Strong Sell Stocks for July 7th

ACCD, DNLI, FSLY, FHB and GH have been added to the Zacks Rank #5 (Strong Sell) List on July 7, 2021.

FHB : 28.64 (+0.53%)
DNLI : 51.00 (-3.59%)
GH : 128.40 (-0.71%)
FSLY : 42.04 (-2.41%)
ACCD : 43.06 (-2.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Guardant Health Inc. is a precision oncology company. It focuses on conquer cancer through use of proprietary blood tests, vast data sets and advanced analytics. The company's Guardant Health Oncology Platform is designed for clinical development, regulatory and reimbursement to drive commercial adoption,...

See More

Key Turning Points

3rd Resistance Point 132.58
2nd Resistance Point 130.95
1st Resistance Point 129.67
Last Price 128.40
1st Support Level 126.76
2nd Support Level 125.13
3rd Support Level 123.85

See More

52-Week High 181.07
Fibonacci 61.8% 148.83
Fibonacci 50% 138.87
Fibonacci 38.2% 128.90
Last Price 128.40
52-Week Low 96.66

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar